Yasmin Hasan to Hematologic Neoplasms
This is a "connection" page, showing publications Yasmin Hasan has written about Hematologic Neoplasms.
Connection Strength
0.166
-
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. Blood Adv. 2023 02 14; 7(3):285-292.
Score: 0.166